Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Rating of "Buy" by Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has earned a consensus rating of "Buy" from the seven analysts that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $31.14.

CPRX has been the topic of a number of recent analyst reports. Truist Financial boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, November 11th. StockNews.com lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, December 24th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Finally, Stephens initiated coverage on Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an "overweight" rating and a $35.00 price target on the stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX traded down $0.20 during mid-day trading on Wednesday, reaching $20.87. 594,934 shares of the company were exchanged, compared to its average volume of 1,155,710. The business has a 50 day simple moving average of $21.80 and a two-hundred day simple moving average of $19.68. The stock has a market capitalization of $2.49 billion, a PE ratio of 17.69, a PEG ratio of 3.35 and a beta of 0.75. Catalyst Pharmaceuticals has a 52 week low of $13.12 and a 52 week high of $24.27.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the company's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the transaction, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Molly Harper sold 17,500 shares of the firm's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $1,754,140 over the last ninety days. 11.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Arizona State Retirement System grew its stake in Catalyst Pharmaceuticals by 2.2% in the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company's stock valued at $461,000 after purchasing an additional 654 shares during the period. GAMMA Investing LLC increased its stake in shares of Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 681 shares during the last quarter. XTX Topco Ltd lifted its stake in Catalyst Pharmaceuticals by 7.5% in the second quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company's stock valued at $172,000 after purchasing an additional 773 shares during the last quarter. Sei Investments Co. lifted its position in shares of Catalyst Pharmaceuticals by 1.3% during the 2nd quarter. Sei Investments Co. now owns 84,458 shares of the biopharmaceutical company's stock valued at $1,308,000 after buying an additional 1,098 shares during the last quarter. Finally, Assetmark Inc. increased its holdings in Catalyst Pharmaceuticals by 2.4% in the 3rd quarter. Assetmark Inc. now owns 72,245 shares of the biopharmaceutical company's stock worth $1,436,000 after acquiring an additional 1,704 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.